- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Interventions
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo
- Drug
- Lead sponsor
- Windtree Therapeutics
- Industry
- Eligibility
- 3 Days to 10 Days
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced May 22, 2026, 4:49 AM EDT